Ascendis Pharma A (ASND) Enterprise Value (2015 - 2026)

Ascendis Pharma A has reported Enterprise Value for 15 years, with the latest figure at -$670.6 million in Q1 2026.

• Quarterly Enterprise Value rose 42.27% year-over-year to -$670.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$670.6 million (up 42.27% YoY) and the FY2025 annual result came in at -$717.1 million, up 47.86% from the prior year.
• Enterprise Value grew to -$670.6 million in Q1 2026 per ASND's latest filing, from -$717.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$429.3 million in Q2 2023 and troughed at -$2.0 billion in Q1 2022.
• A 5-year average of -$970.5 million and a median of -$743.4 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value sank 274.94% in 2022, then jumped 75.37% in 2023.
• Over 5 years, Enterprise Value stood at -$471.1 million in 2022, then slumped by 89.4% to -$892.2 million in 2023, then sank by 54.14% to -$1.4 billion in 2024, then jumped by 47.86% to -$717.1 million in 2025, then gained by 6.48% to -$670.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$670.6 million, -$717.1 million, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.